Overall, the data shows that cell lines from breast and lung cancer are the most sensitive with 66–73% of the breast cell lines having EC50<1 μM to the AKT inhibitors and 20–34% of lung cell lines having EC50 values <1 μM (Figure 1C, Figure 2C). This evidence concerns the gene AKT1 and lung cancer.